首页> 外文期刊>American Journal of Surgical Pathology >Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression
【24h】

Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression

机译:唾液腺腺样囊性癌的结果预测因素临床病理学研究,具有MYB融合与蛋白质表达的相关性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy and it has a high rate of recurrences and a poor long-term prognosis. Our aim was to assess the prognostic factors in ACC and study MYB-NFIB fusion and MYB protein expression in a large retrospective cohort of 135 patients with a median follow-up of 6.3 years. The 5- and 10-year local recurrence-free survival (RFS) rate of 94% and 78%, 5- and 10-year distant metastasis survival rate of 77% and 58%, and 5- and 10-year RFS of 66% and 44%. The following features were identified as adverse prognostic factors of RFS on univariate analysis: large tumor size, solid growth pattern, increased mitoses, positive margin, American Joint Committee on Cancer clinical staging, high-grade transformation, vascular invasion, nuclear atypia, open chromatin, prominent nucleoli, and tumor necrosis. However, on multivariate analysis, only increased mitoses (>= 5/10 high-power fields), any solid growth pattern, and advanced American Joint Committee on Cancer TNM staging were independent adverse predictors for RFS. MYB immunoexpression and MYB-NFIB translocation were common findings in ACC, occurring in 72% and 59% of the tested ACCs, respectively. The sensitivity and specificity of MYB immunohistochemistry in detecting MYB-NFIB fusion was relatively low at 78% sensitivity and 50% specificity. The high prevalence of alterations leading to high expression of the MYB transcription factor family suggests that targeted approaches developed to suppress the expression of these oncogenic transcription factors and/or the transcriptional activity of these proteins would be a rational therapeutic approach to investigate in ACC.
机译:腺样囊性癌(ACC)是第二次最常见的唾液腺恶性肿瘤,其具有高的复发率和较差的长期预后。我们的目的是评估ACC的预后因素,并在大型回顾性群体中研究MyB-NFIB融合和MYB蛋白表达,中位随访6.3岁。 5年和10年的局部复发生存期(RFS)率为94%和78%,5年和10年的远端转移生存率为77%和58%,5年和10年的RFS 66 %和44%。下列特征被鉴定为单变量分析的RFS的不良预后因素:大肿瘤大小,固体生长模式,增加的动力,阳性边缘,美国联合委员会癌症临床分期,高档转化,血管入侵,核紫外线,开放染色质,突出的核仁和肿瘤坏死。然而,在多变量分析上,只有增加的减速(> = 5/10大功率场),任何稳固的生长模式,先进的癌症TNM分期委员会都是RFS的独立不利预测因子。 MYB免疫表达和MYB-NFIB易位是ACC的常见发现,分别为72%和59%的测试ACC。 MYB免疫组织化学检测MYB-NFIB融合的敏感性和特异性相对较低,灵敏度为78%和50%的特异性。导致MYB转录因子家族高表达的改变的高患病率表明,抑制这些致癌转录因子和/或这些蛋白质的转录活性的靶向方法将是调查ACC的合理治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号